Results 211 to 220 of about 774,346 (269)

Clinical Spectrum and Outcomes of SOX1 Antibody‐Associated Paraneoplastic Neurological Syndromes: A Chinese Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background SOX1 antibody‐positive paraneoplastic neurological syndromes (PNS) exhibit significant population‐specific clinical heterogeneity. While Western cohorts predominantly manifest Lambert‐Eaton myasthenic syndrome (65%–80%), comprehensive clinical characterization and treatment response data in Asian populations remain critically ...
Jin‐Long Ye, Zu‐Ying Kuang, Bo Li, Meng‐Qiu Pan, Li‐Hua Zhou, Yang‐Yang Dai, Si‐Fen Xie, Xian‐Guang Lin, Ye‐Peng Hu, Li‐Hong Jiang, Zhan‐Hang Wang, Wei‐Jing Zhang   +11 more
wiley   +1 more source

Albumin-conjugation enables improved tumor targeting of aptamers via SPECT imaging. [PDF]

Mol Ther Nucleic Acids
Yang S, Zheng C, Cheng S, Wen L, Li P, Li J, Lan X, Jiang D.   +7 more
europepmc   +1 more source

Comparative Enzymatic and Stability Assays Reveal GPLG as an Effective Cathepsin B Cleavable Linker for Tumor-Targeting Drug Conjugates. [PDF]

ACS Omega
Cazzaniga G, Zambra M, Bongiolo S, Prpić H, Fasola E, Arrigoni F, Piarulli U, Gazzola S.   +7 more
europepmc   +1 more source

Increased Peripheral T Stem Cell-like Memory Features in Patients with Advanced Solid Tumors Treated with Tumor-Targeting IL-12 Immunocytokine Therapy. [PDF]

Clin Cancer Res
Goswami M, Celades C, Minnar CM, Khelifa AS, Poppe LK, Bracken-Clarke D, Toney NJ, Lynch MT, Marté JL, Gameiro SR, Gulley JL, Schlom J, Donahue RN.   +12 more
europepmc   +1 more source

Innovative design concepts in tumor-targeting peptide-drug conjugates: Insights into emerging applications. [PDF]

Chin Med J (Engl)
Tan R, Yang Z, Xie J, Wu Z, Guo S, Li L, Yin Z, Hua H, Liu M, Li R.   +9 more
europepmc   +1 more source

Effect of a Negatively Charged Amino Acid Linker on the Tumor-Targeting Properties of [¹⁷⁷Lu]Lu-Labeled 4‑<i>p</i>‑(Tolyl)butyric Acid-Conjugated Alpha-Melanocyte-Stimulating Hormone Peptides. [PDF]

ACS Pharmacol Transl Sci
Qiao Z, Xu J, Gallazzi F, Wang J, Smith CJ, Miao Y.   +5 more
europepmc   +1 more source

Selectively triggered: ROS-activated Michael acceptor prodrug strategy to enhance tumor targeting efficacy. [PDF]

Chem Sci
Feng D, Li X, Liu J, Shao X, Liu L, Shi Y, Wang Y, Yu M, Tang S, Deng L, Zhang Y, Xie S, Xu J, Xu S, Yao H.   +14 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Targeting the Tumor-Tumor Microenvironment Crosstalk

Expert Opinion on Therapeutic Targets, 2023
Cancer development and progression is a complex process influenced by co-evolution of the cancer cells and their microenvironment. However, traditional anti-cancer therapy is mostly targeted toward cancer cells. To improve the efficacy of cancer drugs, the complex interactions between the tumor (T) and the tumor microenvironment (TME) should be ...
Sunil S. Badve, Yesim Gökmen-Polar
openaire   +2 more sources

Tumor vasculature-targeting nanomedicines

Acta Biomaterialia, 2021
Uncontrolled tumor growth and subsequent distant metastasis are highly dependent on an adequate nutrient supply from tumor blood vessels, which have relatively different pathophysiological characteristics from those of normal vasculature. Obviously, strategies targeting tumor vasculature, such as anti-angiogenic drugs and vascular disrupting agents ...
Ying, Zhang, Jingni, He
openaire   +2 more sources